Liquidia falls after Q2 profit miss
LQDA•Yutrepia prescription update
The company said its hypertension drug Yutrepia received about 5,900 unique patient prescriptions since its launch in June 2025.
Stock remains up sharply year to date
As of the last close, the stock was more than doubled in value year to date.
Net product sales rise on Yutrepia demand
Net product sales rose to $170.4 million, compared with $6 million last year and above estimates of $168.54 million, boosted by Yutrepia sales.
Liquidia shares fall after quarterly profit miss
Shares of drugmaker Liquidia Corp fell 2.8% to $85.6 after the company reported second-quarter profit of $74.72 million, below analysts' estimates of $77.22 million, according to data compiled by LSEG.
